COMPASS Pathways announces CFO transition
26 Ottobre 2023 - 2:00PM
COMPASS Pathways plc (Nasdaq: CMPS) (“COMPASS” or the “company”), a
biotechnology company dedicated to accelerating patient access to
evidence-based innovation in mental health, today announced that
Mike Falvey, Chief Financial Officer, will depart the company on
November 3, 2023, to pursue other opportunities. Mary-Rose Hughes,
current Vice President of Finance at COMPASS, will assume the role
of interim CFO effective today. COMPASS has begun a search to
select a permanent Chief Financial Officer.
“On behalf of the Board and the company, we thank Mike for his
leadership and the many contributions he made during his tenure at
COMPASS,” said Kabir Nath, Chief Executive Officer of COMPASS
Pathways. “He played a vital role in our recently completed private
placement, which both extended the company's cash runway beyond
expected key phase 3 top-line clinical data readouts and brought
leading biotech investors into our shareholder base. We wish Mike
continued success in his future endeavours.”
Ms. Hughes joined COMPASS as its second finance team employee in
May 2020. She has deep knowledge of COMPASS’s business and has led
the creation and operation of the company’s financial operations,
treasury, tax, financial planning and analysis, and external
reporting. She played a key role in COMPASS’s IPO, follow-on public
equity offering, term loan facility, and private placement
financing. Prior to joining COMPASS, Ms. Hughes began her career in
public accounting with Ernst and Young and was Head of Financial
Reporting for Veolia UK & Ireland. She earned her LLB in Law at
Queen’s University, Belfast and her ACA qualification from
Chartered Accountants, Ireland.
About COMPASS PathwaysCOMPASS Pathways plc
(Nasdaq: CMPS) is a biotechnology company dedicated to accelerating
patient access to evidence-based innovation in mental health. Our
focus is on improving the lives of those who are suffering with
mental health challenges and who are not helped by current
treatments. We are pioneering the development of a new model of
psilocybin therapy, in which our proprietary formulation of
synthetic psilocybin, COMP360, is administered in conjunction with
psychological support. COMP360 has been designated a Breakthrough
Therapy by the U.S. Food and Drug Administration (FDA) and has
received Innovative Licensing and Access Pathway (ILAP) designation
in the UK for treatment-resistant depression (TRD). We have
commenced a phase 3 clinical program of COMP360 psilocybin therapy
in TRD, the largest randomized, controlled, double-blind psilocybin
therapy clinical program ever conducted. Previously, we completed a
phase 2b study with top line data showing a statistically
significant (p<0.001) and clinically relevant improvement in
depressive symptom severity after three weeks for patients who
received a single 25mg dose of COMP360 psilocybin with
psychological support. We are also conducting phase 2 clinical
studies of COMP360 psilocybin therapy for post-traumatic stress
disorder (PTSD) and anorexia nervosa. COMPASS is headquartered in
London, UK, with offices in New York and San Francisco in the
United States. Our vision is a world of mental
wellbeing. www.compasspathways.com.
Forward-looking statementsThis press release
contains forward-looking statements within the meaning of the
Private Securities Litigation Reform Act of 1995, as amended. In
some cases, forward-looking statements can be identified by
terminology such as “will”, “may”, “might”, “could”, “would”,
“should”, “expect”, “intend”, “plan”, “objective”, “anticipate”,
“believe”, “contemplate”, “estimate”, “predict”, “potential”,
“continue” and “ongoing,” or the negative of these terms or other
comparable terminology, although not all forward-looking statements
contain these words. Forward-looking statements include express or
implied statements relating to, among other things, our
expectations regarding our financial position, funding requirements
and cash runway, COMPASS’s expectations regarding its plans for a
new Chief Financial Officer and COMPASS’s expectations regarding
its COMPASS’s pivotal phase 3 program or other trials to support
regulatory filings and approvals. The forward-looking statements in
this press release are neither promises nor guarantees, and you
should not place undue reliance on these forward-looking statements
because they involve known and unknown risks, uncertainties, and
other factors, many of which are beyond COMPASS’s control and which
could cause actual results, levels of activity, performance or
achievements to differ materially from those expressed or implied
by these forward-looking statements.
These risks, uncertainties, and other factors include, among
others: market risks and other market conditions; the hiring market
and timing for the Company to find a new Chief Financial Officer;
clinical development is lengthy and expensive process with
uncertain outcomes, and therefore our clinical trials may be
delayed or terminated and may be more costly than expected; we will
require substantial additional funding to achieve our business
goals and if we are unable to obtain this funding when needed and
on acceptable terms, we could be forced to delay, limit or
terminate our product development efforts; our efforts to obtain
marketing approval from the applicable regulatory authorities in
any jurisdiction for COMP360 or any future product candidates may
be unsuccessful; establishing, maintaining, defending and enforcing
our patents and other intellectual property rights covering our
investigational COMP360 psilocybin therapy may be challenging and
costly and our efforts to protect our patents and other
intellectual property rights may be unsuccessful; our efforts to
commercialize and to obtain coverage and reimbursement for our
investigational COMP360 psilocybin therapy, if approved, may be
unsuccessful; our ability to successfully manage senior management
changes; economic and geopolitical uncertainties and those risks
and uncertainties described under the heading “Risk Factors” in
COMPASS’s most recent annual report on Form 10-K or quarterly
report on Form 10-Q and in other reports we have filed with the
U.S. Securities and Exchange Commission (“SEC”), which are
available on the SEC’s website at www.sec.gov. Except as required
by law, COMPASS disclaims any intention or responsibility for
updating or revising any forward-looking statements contained in
this press release in the event of new information, future
developments or otherwise. These forward-looking statements are
based on COMPASS’s current expectations and speak only as of the
date hereof.
Enquiries:Media: Amy Lawrence,
media@compasspathways.com, +44 7813 777 919 Investors: Stephen
Schultz, stephen.schultz@compasspathways.com, +1 401 290 7324
Grafico Azioni COMPASS Pathways (NASDAQ:CMPS)
Storico
Da Apr 2024 a Mag 2024
Grafico Azioni COMPASS Pathways (NASDAQ:CMPS)
Storico
Da Mag 2023 a Mag 2024